{"id":7755,"date":"2025-09-15T16:17:13","date_gmt":"2025-09-15T23:17:13","guid":{"rendered":"https:\/\/www.promisdx.com\/?p=7755"},"modified":"2025-10-30T14:44:22","modified_gmt":"2025-10-30T21:44:22","slug":"promis-diagnostics-earlytect-bcd-recognized-in-2025-aua-sufu-microhematuria-guideline-as-a-validated-urinary-biomarker-option","status":"publish","type":"post","link":"https:\/\/www.promisdx.com\/?p=7755","title":{"rendered":"Promis Diagnostics&#8217; EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row full_width=&#8221;stretch_row_content_no_spaces&#8221;][vc_column][vc_empty_space height=&#8221;&#8221; el_class=&#8221;header_news&#8221; css=&#8221;.vc_custom_1678221691977{background-image: url(https:\/\/www.promisdx.com\/wp-content\/uploads\/2022\/12\/newstemplateheader.png?id=6109) !important;}&#8221;][\/vc_column][\/vc_row][vc_section full_width=&#8221;stretch_row&#8221;][vc_row full_width=&#8221;stretch_row&#8221; layout=&#8221;boxed&#8221; css=&#8221;.vc_custom_1679355419891{margin-top: 1vw !important;}&#8221;][vc_column][vc_custom_heading text=&#8221;Promis Diagnostics&#8217; EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option&#8221; font_container=&#8221;tag:h2|text_align:left|color:%230074b7|line_height:1&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:400%20regular%3A400%3Anormal&#8221; el_class=&#8221;min-txt-body-head&#8221;][vc_column_text el_class=&#8221;body-text&#8221;]<\/p>\n<p style=\"text-align: left;\"><strong>Irvine, California, September<\/strong><strong> 15, 2025<\/strong><\/p>\n<p>Promis Diagnostics today announced that its flagship bladder cancer test, EarlyTect BCD (PLA 0452U), has been highlighted in the 2025 American Urological Association (AUA) \/ Society of Urodynamics, Female Pelvic Medicine &amp; Urogenital Reconstruction (SUFU) Microhematuria Guideline as one of the urinary biomarkers with strong negative predictive value (NPV) for ruling out bladder cancer in patients with microhematuria.<br \/>\nIn the updated guideline, the Panel reinforced the use of urine cytology and validated urinary biomarkers as optional tools for intermediate-risk microhematuria patients who wish to avoid cystoscopy. EarlyTect BCD demonstrated an NPV of 97.6%\u201398.7% across 1,465 patients, one of the largest validation cohorts reported among urine-based tests.<\/p>\n<p><strong>Key Strengths Recognized<\/strong><\/p>\n<p style=\"padding-left: 40px;\"><em><strong>&#8211;<\/strong> High Negative Predictive Value<\/em><br \/>\nWith nearly 99% NPV, EarlyTect BCD provides physicians with confidence to safely defer cystoscopy in appropriately selected patients intermediate risk population.<br \/>\n<em><strong>&#8211;<\/strong> Validated in Large Diverse Cohorts<\/em><br \/>\nAs shown in the AUA\/SUFU guideline table of validated urinary biomarkers, EarlyTect BCD is validated in the largest study population to date among urine-based bladder cancer tests \u2014 over 1,400 patients across both microhematuria and gross hematuria cohorts \u2014 underscoring its unmatched real-world applicability.<br \/>\n<em><strong>&#8211;<\/strong> Clinical Alignment with AUA Guideline Pathway<\/em><br \/>\nThe updated guideline specifically enables the use of validated biomarkers for intermediate-risk microhematuria. In this setting, EarlyTect BCD is uniquely positioned to reduce unnecessary invasive cystoscopies while ensuring patient safety and physician confidence.<\/p>\n<p>EarlyTect BCD\u2019s NPV values in the AUA\/SUFU Guidelines are not only comparable but demonstrate strong performance alongside other validated urinary biomarkers. While the reported values may appear conservative due to the high prevalence of bladder cancer (19.9%) in the cohort, this reflects the patient population studied rather than test performance. Because NPV increases as prevalence decreases, EarlyTect BCD achieves NPVs exceeding 99% in lower-prevalence settings that reflect real-world urology practice (2\u201310%), aligning with or surpassing peer assays. This recognition underscores EarlyTect BCD\u2019s reliability across diverse hematuria populations..<\/p>\n<p>With its recognition in the 2025 AUA\/SUFU Microhematuria Guideline, EarlyTect BCD represents a major step forward in providing patients and physicians with a reliable option for bladder cancer evaluation. Promis Diagnostics is committed to further expanding the clinical evidence base and working toward broader adoption and reimbursement to ensure patients benefit from early, accurate and non-invasive testing.<\/p>\n<p>For a more detailed article, read here: <a href=\"https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/microhematuria\">https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/microhematuria<\/a>[\/vc_column_text][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row full_width=&#8221;stretch_row_content_no_spaces&#8221;][vc_column][vc_empty_space height=&#8221;&#8221; el_class=&#8221;header_news&#8221; css=&#8221;.vc_custom_1678221691977{background-image: url(https:\/\/www.promisdx.com\/wp-content\/uploads\/2022\/12\/newstemplateheader.png?id=6109) !important;}&#8221;][\/vc_column][\/vc_row][vc_section full_width=&#8221;stretch_row&#8221;][vc_row full_width=&#8221;stretch_row&#8221; layout=&#8221;boxed&#8221; css=&#8221;.vc_custom_1679355419891{margin-top: 1vw !important;}&#8221;][vc_column][vc_custom_heading text=&#8221;Promis Diagnostics&#8217; EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option&#8221; font_container=&#8221;tag:h2|text_align:left|color:%230074b7|line_height:1&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:400%20regular%3A400%3Anormal&#8221; el_class=&#8221;min-txt-body-head&#8221;][vc_column_text el_class=&#8221;body-text&#8221;] Irvine, California, September 15, 2025 Promis Diagnostics today announced that its flagship bladder cancer test, EarlyTect BCD (PLA 0452U), has been highlighted [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":7766,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[458],"tags":[],"class_list":["post-7755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Promis Diagnostics&#039; EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option - Promis DX<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.promisdx.com\/?p=7755\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Promis Diagnostics&#039; EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option - Promis DX\" \/>\n<meta property=\"og:description\" content=\"[vc_row full_width=&#8221;stretch_row_content_no_spaces&#8221;][vc_column][vc_empty_space height=&#8221;&#8221; el_class=&#8221;header_news&#8221; css=&#8221;.vc_custom_1678221691977{background-image: url(https:\/\/www.promisdx.com\/wp-content\/uploads\/2022\/12\/newstemplateheader.png?id=6109) !important;}&#8221;][\/vc_column][\/vc_row][vc_section full_width=&#8221;stretch_row&#8221;][vc_row full_width=&#8221;stretch_row&#8221; layout=&#8221;boxed&#8221; css=&#8221;.vc_custom_1679355419891{margin-top: 1vw !important;}&#8221;][vc_column][vc_custom_heading text=&#8221;Promis Diagnostics&#8217; EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option&#8221; font_container=&#8221;tag:h2|text_align:left|color:%230074b7|line_height:1&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:400%20regular%3A400%3Anormal&#8221; el_class=&#8221;min-txt-body-head&#8221;][vc_column_text el_class=&#8221;body-text&#8221;] Irvine, California, September 15, 2025 Promis Diagnostics today announced that its flagship bladder cancer test, EarlyTect BCD (PLA 0452U), has been highlighted [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.promisdx.com\/?p=7755\" \/>\n<meta property=\"og:site_name\" content=\"Promis DX\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/promisdx\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-15T23:17:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-30T21:44:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.promisdx.com\/wp-content\/uploads\/2025\/09\/istockphoto-700211920-1024x1024-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Promis DX\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Promis DX\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.promisdx.com\/?p=7755#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7755\"},\"author\":{\"name\":\"Promis DX\",\"@id\":\"https:\/\/www.promisdx.com\/#\/schema\/person\/c085d00d0271456e681a0f53a6ddc637\"},\"headline\":\"Promis Diagnostics&#8217; EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option\",\"datePublished\":\"2025-09-15T23:17:13+00:00\",\"dateModified\":\"2025-10-30T21:44:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7755\"},\"wordCount\":516,\"publisher\":{\"@id\":\"https:\/\/www.promisdx.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7755#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2025\/09\/istockphoto-700211920-1024x1024-1.jpg?fit=1024%2C700&ssl=1\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.promisdx.com\/?p=7755\",\"url\":\"https:\/\/www.promisdx.com\/?p=7755\",\"name\":\"Promis Diagnostics' EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option - Promis DX\",\"isPartOf\":{\"@id\":\"https:\/\/www.promisdx.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7755#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7755#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2025\/09\/istockphoto-700211920-1024x1024-1.jpg?fit=1024%2C700&ssl=1\",\"datePublished\":\"2025-09-15T23:17:13+00:00\",\"dateModified\":\"2025-10-30T21:44:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7755#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.promisdx.com\/?p=7755\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.promisdx.com\/?p=7755#primaryimage\",\"url\":\"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2025\/09\/istockphoto-700211920-1024x1024-1.jpg?fit=1024%2C700&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2025\/09\/istockphoto-700211920-1024x1024-1.jpg?fit=1024%2C700&ssl=1\",\"width\":1024,\"height\":700,\"caption\":\"Scientist Working in The Laboratory\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.promisdx.com\/?p=7755#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.promisdx.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Promis Diagnostics&#8217; EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.promisdx.com\/#website\",\"url\":\"https:\/\/www.promisdx.com\/\",\"name\":\"PromisDx\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.promisdx.com\/#organization\"},\"alternateName\":\"Promis Dx\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.promisdx.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.promisdx.com\/#organization\",\"name\":\"Promis DX\",\"url\":\"https:\/\/www.promisdx.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.promisdx.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.promisdx.com\/wp-content\/uploads\/2021\/02\/PromisDx_Logo_2_RGB.png\",\"contentUrl\":\"https:\/\/www.promisdx.com\/wp-content\/uploads\/2021\/02\/PromisDx_Logo_2_RGB.png\",\"width\":2223,\"height\":901,\"caption\":\"Promis DX\"},\"image\":{\"@id\":\"https:\/\/www.promisdx.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/promisdx\",\"https:\/\/www.linkedin.com\/company\/promisdx\",\"https:\/\/www.instagram.com\/promisdx\/?igshid=YmMyMTA2M2Y\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.promisdx.com\/#\/schema\/person\/c085d00d0271456e681a0f53a6ddc637\",\"name\":\"Promis DX\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.promisdx.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/879c3dc78687f595be7e01d63d40db85133d212512634d874b308c32f288b6e4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/879c3dc78687f595be7e01d63d40db85133d212512634d874b308c32f288b6e4?s=96&d=mm&r=g\",\"caption\":\"Promis DX\"},\"url\":\"https:\/\/www.promisdx.com\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Promis Diagnostics' EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option - Promis DX","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.promisdx.com\/?p=7755","og_locale":"en_US","og_type":"article","og_title":"Promis Diagnostics' EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option - Promis DX","og_description":"[vc_row full_width=&#8221;stretch_row_content_no_spaces&#8221;][vc_column][vc_empty_space height=&#8221;&#8221; el_class=&#8221;header_news&#8221; css=&#8221;.vc_custom_1678221691977{background-image: url(https:\/\/www.promisdx.com\/wp-content\/uploads\/2022\/12\/newstemplateheader.png?id=6109) !important;}&#8221;][\/vc_column][\/vc_row][vc_section full_width=&#8221;stretch_row&#8221;][vc_row full_width=&#8221;stretch_row&#8221; layout=&#8221;boxed&#8221; css=&#8221;.vc_custom_1679355419891{margin-top: 1vw !important;}&#8221;][vc_column][vc_custom_heading text=&#8221;Promis Diagnostics&#8217; EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option&#8221; font_container=&#8221;tag:h2|text_align:left|color:%230074b7|line_height:1&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:400%20regular%3A400%3Anormal&#8221; el_class=&#8221;min-txt-body-head&#8221;][vc_column_text el_class=&#8221;body-text&#8221;] Irvine, California, September 15, 2025 Promis Diagnostics today announced that its flagship bladder cancer test, EarlyTect BCD (PLA 0452U), has been highlighted [&hellip;]","og_url":"https:\/\/www.promisdx.com\/?p=7755","og_site_name":"Promis DX","article_publisher":"https:\/\/www.facebook.com\/promisdx","article_published_time":"2025-09-15T23:17:13+00:00","article_modified_time":"2025-10-30T21:44:22+00:00","og_image":[{"width":1024,"height":700,"url":"https:\/\/www.promisdx.com\/wp-content\/uploads\/2025\/09\/istockphoto-700211920-1024x1024-1.jpg","type":"image\/jpeg"}],"author":"Promis DX","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Promis DX","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.promisdx.com\/?p=7755#article","isPartOf":{"@id":"https:\/\/www.promisdx.com\/?p=7755"},"author":{"name":"Promis DX","@id":"https:\/\/www.promisdx.com\/#\/schema\/person\/c085d00d0271456e681a0f53a6ddc637"},"headline":"Promis Diagnostics&#8217; EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option","datePublished":"2025-09-15T23:17:13+00:00","dateModified":"2025-10-30T21:44:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.promisdx.com\/?p=7755"},"wordCount":516,"publisher":{"@id":"https:\/\/www.promisdx.com\/#organization"},"image":{"@id":"https:\/\/www.promisdx.com\/?p=7755#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2025\/09\/istockphoto-700211920-1024x1024-1.jpg?fit=1024%2C700&ssl=1","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.promisdx.com\/?p=7755","url":"https:\/\/www.promisdx.com\/?p=7755","name":"Promis Diagnostics' EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option - Promis DX","isPartOf":{"@id":"https:\/\/www.promisdx.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.promisdx.com\/?p=7755#primaryimage"},"image":{"@id":"https:\/\/www.promisdx.com\/?p=7755#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2025\/09\/istockphoto-700211920-1024x1024-1.jpg?fit=1024%2C700&ssl=1","datePublished":"2025-09-15T23:17:13+00:00","dateModified":"2025-10-30T21:44:22+00:00","breadcrumb":{"@id":"https:\/\/www.promisdx.com\/?p=7755#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.promisdx.com\/?p=7755"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.promisdx.com\/?p=7755#primaryimage","url":"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2025\/09\/istockphoto-700211920-1024x1024-1.jpg?fit=1024%2C700&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2025\/09\/istockphoto-700211920-1024x1024-1.jpg?fit=1024%2C700&ssl=1","width":1024,"height":700,"caption":"Scientist Working in The Laboratory"},{"@type":"BreadcrumbList","@id":"https:\/\/www.promisdx.com\/?p=7755#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.promisdx.com\/"},{"@type":"ListItem","position":2,"name":"Promis Diagnostics&#8217; EarlyTect BCD Recognized in 2025 AUA\/SUFU Microhematuria Guideline as a Validated Urinary Biomarker Option"}]},{"@type":"WebSite","@id":"https:\/\/www.promisdx.com\/#website","url":"https:\/\/www.promisdx.com\/","name":"PromisDx","description":"","publisher":{"@id":"https:\/\/www.promisdx.com\/#organization"},"alternateName":"Promis Dx","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.promisdx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.promisdx.com\/#organization","name":"Promis DX","url":"https:\/\/www.promisdx.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.promisdx.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.promisdx.com\/wp-content\/uploads\/2021\/02\/PromisDx_Logo_2_RGB.png","contentUrl":"https:\/\/www.promisdx.com\/wp-content\/uploads\/2021\/02\/PromisDx_Logo_2_RGB.png","width":2223,"height":901,"caption":"Promis DX"},"image":{"@id":"https:\/\/www.promisdx.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/promisdx","https:\/\/www.linkedin.com\/company\/promisdx","https:\/\/www.instagram.com\/promisdx\/?igshid=YmMyMTA2M2Y"]},{"@type":"Person","@id":"https:\/\/www.promisdx.com\/#\/schema\/person\/c085d00d0271456e681a0f53a6ddc637","name":"Promis DX","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.promisdx.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/879c3dc78687f595be7e01d63d40db85133d212512634d874b308c32f288b6e4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/879c3dc78687f595be7e01d63d40db85133d212512634d874b308c32f288b6e4?s=96&d=mm&r=g","caption":"Promis DX"},"url":"https:\/\/www.promisdx.com\/?author=4"}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2025\/09\/istockphoto-700211920-1024x1024-1.jpg?fit=1024%2C700&ssl=1","_links":{"self":[{"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/posts\/7755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7755"}],"version-history":[{"count":6,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/posts\/7755\/revisions"}],"predecessor-version":[{"id":7795,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/posts\/7755\/revisions\/7795"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/media\/7766"}],"wp:attachment":[{"href":"https:\/\/www.promisdx.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}